Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRN, AHPA say FDA should consider combo products

This article was originally published in The Tan Sheet

Executive Summary

FDA should allow supplement and drug combination products in the marketplace, executives from the Council for Responsible Nutrition and the American Herbal Products Association say at a Jan. 30 Food, Drug and Law Institute conference in Washington. "It's to FDA's advantage to help the industry" market combination products because they will benefit the public health, CRN President Steve Mister notes. Mister says FDA should advise all manufacturers on how to comply so they have "equal footing" in the marketplace. AHPA President Michael McGuffin says, "Don't tell us what we can't do. Tell us how we can do it, in a reasonable and responsible manner." FDA in October 2008 warned Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs (1"The Tan Sheet" Nov. 3, 2008, p. 9)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel